

Available online at www.sciencedirect.com



Tetrahedron Letters

Tetrahedron Letters 48 (2007) 61–64

# Efficient (bromodimethyl)sulfonium bromide mediated synthesis of benzimidazoles $\hat{z}$

Biswanath Das,\* Harish Holla and Yallamalla Srinivas

Organic Chemistry Division-I, Indian Institute of Chemical Technology, Hyderabad 500 007, India

Received 18 September 2006; revised 20 October 2006; accepted 2 November 2006 Available online 21 November 2006

Abstract—Benzimidazoles have been efficiently synthesized in high yields by treatment of 1,2-phenylenediamine with aldehydes using (bromodimethyl)sulfonium bromide at room temperature. © 2006 Elsevier Ltd. All rights reserved.

### 1. Introduction

The benzimidazole moiety is found in various bioactive compounds having antiviral, antiulcer, antihypertension and anticancer properties.<sup>[1](#page-3-0)</sup> General methods for the synthesis of benzimidazoles involve treatment of 1,2 phenylenediamines with carboxylic acids or various derivatives under strongly acidic conditions or with aldehydes followed by oxidation.[2,3](#page-3-0)

# 2. Results and discussion

In continuation of our work<sup>[4](#page-3-0)</sup> on the development of useful synthetic methodologies, we have observed that benzimidazoles can be synthesized efficiently by treatment of 1,2-phenylenediamine with aldehydes using (bromodimethyl)sulfonium bromide at room temperature (Scheme 1).

Several aldehydes (aromatic, heteroaromatic and aliphatic) underwent the above conversion to form a series of benzimidazoles ([Table 1\)](#page-1-0). Aromatic aldehydes containing both electron-donating and electron-withdrawing groups worked well. Aliphatic  $\alpha$ ,  $\beta$ -unsaturated aldehydes ([Table 1,](#page-1-0) entry 3m) also afforded the desired products in high yields. The method is suitable for the preparation of benzimidazoles from an acid sensitive aldehyde such as furfuraldehyde (entry 3n) and the sterically hindered aldehyde 2-naphthaldehyde (entry 3o). The reaction conditions are mild and the experimental procedure is simple. The products were formed in high yields (72–  $91\%$ ). The structures of the products were determined from their spectral  $(^1H$  NMR, IR and MS) data.

(Bromodimethyl)sulfonium bromide is an inexpensive reagent. It has been used mainly as a catalyst but its scope has not been fully explored.<sup>[5](#page-3-0)</sup> Here it has been applied for oxidative dehydrogenation of the cyclic



Scheme 1.

*Keywords*: Aldehyde; Diamine; (Bromodimethyl)sulfonium bromide; Benzimidazole.<br>\* Part 119 in the series, 'Studies on novel synthetic methodologies'. IICT Communication No. 061021.

<sup>\*</sup> Corresponding author. Tel./fax: +91 40 27160512; e-mail: [biswanathdas@yahoo.com](mailto:biswanathdas@yahoo.com)

<sup>0040-4039/\$ -</sup> see front matter © 2006 Elsevier Ltd. All rights reserved. doi:10.1016/j.tetlet.2006.11.018



<span id="page-1-0"></span>



<sup>a</sup> The structures of the products were determined from their spectral (<sup>1</sup>H NMR, IR and MS) data.

intermediates formed from the condensation of 1,2 phenylenediamine and aldehydes.

<span id="page-2-0"></span>Table 1 (continued)

In conclusion, (bromodimethyl)sulfonium bromide has been employed here for the first time as a mild and efficient reagent for the convenient preparation of benzimidazoles in high yields from 1,2-phenylenediamine and a wide variety of aldehydes.

#### 3. General experimental procedure

To a mixture of an aldehyde (0.5 mmol) and 1,2-phenylenediamine (0.6 mmol) in acetonitrile (5 mL) under a nitrogen atmosphere, (bromodimethyl)sulfonium bromide (0.5 mmol) was added. The mixture was stirred at room temperature and the reaction was monitored by TLC. After completion, the solvent was evaporated and saturated aqueous  $NaHCO<sub>3</sub>$  (10 mL) was added. The mixture was extracted with EtOAc  $(3 \times 10 \text{ mL})$ and the extract was dried and concentrated. The residue was subjected to column chromatography (silica gel, hexane–EtOAc) to obtain the pure benzimidazole.

The spectral  $(^1H$  NMR, IR and MS) data of some representative benzimidazoles are given below.

# 3.1. Compound 3g

<sup>1</sup>H NMR (CDCl<sub>3</sub> + DMSO- $d_6$ ):  $\delta$  12.70 (1H, br s), 8.08  $(2H, d, J = 8.0 \text{ Hz})$ , 7.59 (1H, m), 7.26–7.20 (3H, m),  $7.18-7.04$  (2H, m); IR (KBr):  $\nu$  3188, 2981, 1624 cm<sup>-1</sup> ; FABMS:  $m/z$  231 (<sup>37</sup>Cl [M+H]<sup>+</sup>), 229 (<sup>35</sup>Cl [M+H]<sup>+</sup>); Anal. Calcd for  $C_{13}H_9N_2Cl$ : C, 68.27; H, 3.94; N, 12.25. Found: C, 68.42; H, 3.86; N, 12.38.

# 3.2. Compound 3m

<sup>1</sup>H NMR (CDCl<sub>3</sub> + DMSO- $d_6$ ):  $\delta$  11.82 (1H, br s), 7.62–7.21 (2H, m), 7.18–7.01 (2H, m), 6.42 (1H, t,  $J = 7.0$  Hz), 2.29–2.22 (2H, m), 2.16 (3H, s), 1.08 (3H, t,  $J = 7.0$  Hz); IR (KBr):  $v$  3064, 2963, 2923,  $1648 \text{ cm}^{-1}$ ; FABMS:  $m/z$  187 [M+H]<sup>+</sup>; Anal. Calcd for  $C_{12}H_{14}N_2$ : C, 77.42; H, 7.53; N, 15.05. Found: C, 77.68; H, 7.64; N, 15.23.

# 3.3. Compound 3o

<sup>1</sup>H NMR (CDCl<sub>3</sub> + DMSO- $d_6$ ):  $\delta$  11.86 (1H, br s), 8.74  $(1H, br s), 8.38$   $(1H, dd, J = 8.0, 2.0 Hz), 8.02–7.90$   $(3H,$ m), 7.69–7.52 (4H, m), 7.26–7.18 (2H, m); IR (KBr):  $\nu$ 3056, 2924, 2853, 1624 cm<sup>-1</sup>; FABMS:  $m/z$  245  $[M+H^+;$  Anal. Calcd for C<sub>17</sub>H<sub>12</sub>N<sub>2</sub>: C, 83.61; H, 4.92; N, 11.47. Found: C, 83.87; H, 4.88; N, 11.61.

# <span id="page-3-0"></span>3.4. Compound 3p

<sup>1</sup>H NMR (CDCl<sub>3</sub> + DMSO- $d_6$ ):  $\delta$  11.79 (1H, br s), 9.28 (1H, s), 8.16 (1H, s), 7.68 (1H, m), 7.58–7.46 (2H, m), 7.24–7.20 (3H, m), 2.56 (3H, s); IR (KBr): v 3308, 3048, 2923, 2854, 1639 cm<sup>-1</sup>; FABMS:  $m/z$  277  $[M+H]^+$ ; Anal. Calcd for C<sub>17</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub>: C, 73.91; H, 4.35; N, 10.14. Found: C, 73.98; H, 4.42; N, 10.23.

# Acknowledgements

The authors thank UGC and CSIR, New Delhi, for financial assistance.

#### References and notes

- 1. (a) Gravatt, G. L.; Baguley, B. C.; Wilson, W. R.; Denny, W. A. J. Med. Chem. 1994, 37, 4338; (b) Kim, J. S.; Gatto, B.; Yu, C.; Liu, A.; Liu, L. F.; La Voie, E. J. J. Med. Chem. 1996, 39, 992; (c) Roth, T.; Morningstar, M. L.; Boyer, P. L.; Hughes, S. H.; Buckheit, R. W., Jr.; Michejda, C. J. J. Med. Chem. 1997, 40, 4199; (d) Horton, D. A.; Bourne, G. T.; Smythe, M. L. Chem. Rev. 2003, 103, 893.
- 2. (a) Middleton, R. W.; Wibberley, D. G. J. Heterocycl. Chem. 1980, 17, 1757; (b) Hisano, T.; Ichikawa, M.;

Tsumoto, K.; Tasaki, M. Chem. Pharm. Bull. 1982, 30, 2996; (c) Fairley, T. A.; Tidwell, R. R.; Donkor, I.; Naiman, N. A.; Ohemeng, K. A.; Lombardy, R. J.; Bentley, J. A.; Cory, M. J. Med. Chem. 1993, 36, 1746; (d) Czarny, A.; Wilson, W. D.; Boykin, D. W. J. Heterocycl. Chem. 1996, 33, 1393.

- 3. (a) Stephens, F. F.; Bower, J. D. J. Chem. Soc. 1949, 2971; (b) Chikashita, H.; Nishida, S.; Miyazaki, M.; Morita, Y.; Itoh, K. Bull. Chem. Soc. Jpn. 1987, 60, 737; (c) Kumar, S.; Kansal, V.; Bhaduri, A. Indian J. Chem. 1991, 20B, 254; (d) Patzold, F.; Zeuner, F.; Heyer, T. H.; Niclas, H.-J. Synth. Commun. 1992, 22, 281; (e) Lombardy, R. L.; Tanious, F. A.; Ramachandran, K.; Tidwell, R. R.; Wilson, W. D. J. Med. Chem. 1996, 39, 1452; (f) Beaulieu, P. L.; Hache, B.; von Moos, E. Synthesis 2003, 1683.
- 4. (a) Das, B.; Reddy, V. S. Catal. Commun. 2006, 7, 997; (b) Das, B.; Venkateswarlu, K.; Holla, H.; Krishnaiah, M. J. Mol. Catal. A: Chem. 2006, 253, 107; (c) Das, B.; Reddy, K. R.; Ramu, R.; Thirupathi, P.; Ravikanth, B. Synlett 2006, 1756; (d) Das, B.; Ravikanth, B.; Ramu, R.; Rao, B. V. Chem. Pharm. Bull. 2006, 54, 1044; (e) Das, B.; Chowdhury, N.; Banerjee, J.; Majhi, A.; Mahender, G. Chem. Lett. 2006, 35, 358.
- 5. (a) Furukawa, N.; Inoue, T.; Aida, T.; Oae, S. J. Chem. Soc., Chem. Commun. 1973, 212; (b) Olah, G. A.; Yashwant, D. V.; Massoud, A.; Suryaprakash, G. A. Synthesis 1979, 720; (c) Khan, A. T.; Mondal, E.; Ghosh, S.; Islam, S. Eur. J. Org. Chem. 2004, 2002.